en · de · es · fr · pt
sermorelin-notes.peptides9002.com › Faq › Bremelanotide Background And Receptor Pharmacology — 2026 Update

Bremelanotide Background And Receptor Pharmacology — 2026 Update

By Editorial Desk · published 2025-09-30 · last reviewed 2025-11-18 · Faq

The short version of Cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.

Bremelanotide Background and Receptor Pharmacology

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.

PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.

Melanocortin Receptor Pharmacology

Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.

The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.

Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.

Pt-141 at a glance

PropertyValueNotes
Research codePT-141Used in early literature before the generic name became common
Generic nameBremelanotideInternational nonproprietary name
Peptide classCyclic heptapeptideSeven residues joined by a lactam bridge
Primary receptorMC4RLower affinity reported at MC1R, MC3R and MC5R
Route studied clinicallySubcutaneous injectionIntranasal route was abandoned after pressor effects

Melanocortin Receptor Agonist Pharmacology

Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.

Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.

Related pages on this site

Chemical Identity of Bremelanotide

The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

Receptor Mechanism And Pharmacokinetics

The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.

After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.

Reference notes

== Technology == Digital agriculture encompasses a wide range of technologies, most of which have multiple applications along the agricultural value chain. These technologies include, but are not limited to:

===== Rpn1 ===== Ubiquitin binds Rpn1 via two sites, termed the T1 and T2 sites that were identified using NMR. Rpn1 also provides a docking site for Ubp6. The affinities for ubiquitin for these receptors in isolation has been measured through a variety of methods. They are all in the micromolar range, however a substrate that has both a ubiquitin signal and an unstructured region has a Michaelis menten constant in the hundreds of nanomolar range, suggesting that the unstructured region in key in engaging a substrate.

==== Timber rattlesnake ==== The timber rattlesnake, (Crotalus horridus), is a species of venomous pit viper endemic to eastern North America. This is the only rattlesnake species in most of the populous northeastern United States and is second only to its cousins to the west, the prairie rattlesnake, as the most northerly distributed venomous snake in North America. No subspecies are currently recognized.

On the night of 24/25 July 1261, Strategopoulos and his men approached the city walls and hid at a monastery near the Gate of the Spring. Strategopoulos sent a detachment of his men, led by some of the thelematarioi, to make their way to the city through a secret passage. This afforded them the opportunity to attack the walls from the inside, which surprised the guards and opened the gate, giving the Nicaean forces an entry into the city. The Latins were taken completely unaware, and after a short struggle, the Nicaeans gained control of the Theodosian land walls. As news of this spread across the city, the Latin inhabitants, from Emperor Baldwin II downwards, hurriedly rushed to the harbours of the Golden Horn, hoping to escape by ship. At the same time, Strategopoulos' men set fire to the Venetian buildings and warehouses along the coast to prevent them from landing there. Due to the timely arrival of the returning Venetian fleet, many of the Latins managed to evacuate to the still Latin-held parts of Greece, marking the end of the Latin occupation with the city's restoration to the Byzantines.

This limitation has motivated the incorporation of selectivity-enhancing functional groups directly into the probe design. In the case of metalloproteases, active enzymes coordinate a catalytic metal ion. By adding a metal-chelating moiety to the probe scaffold, photoreactive ABPs can be biased toward the catalytically competent, metal-bound form of the enzyme, thereby improving discrimination between active and inactive form. Another major design challenge is achieving sufficient reactivity to label the intended enzyme without indiscriminate modification of unrelated proteins. Strategies such as masked warheads, which become activated only in the presence of a target enzyme, have been developed to improve specificity.

Sources: en.wikipedia.org

Notes from published material

Madison's policy of neutrality favored insurgents and this, along with the border-line problems in North America, led to a situation of pre-war tension with Spain. This situation forced the United States to act very cautiously in the Spanish-American issue, since it was trying to avoid at all costs to give an excuse for European intervention. At the end, the recognition in 1822 also was very delicate, at the international level the North American position against European powers. Despite the carefulness of the United States to not stoke European powers, in 1823 President James Monroe established the Monroe Doctrine. This was a decree to stop any new European colonialism in the Americas by threat of military intervention. It was outlined as noncolonialism (keeping Europe away from establishing new colonies), keeping the United States out of strictly European affairs, and to treat any potential invasions of American countries as if an affront to the United States itself. This was mostly to protect American interests. Due to newspaper romanticism, the American public overwhelmingly backed these revolts and thus were very sympathetic to the Latin American cause. Simón Bolívar became a household name throughout the United States as many saw him as the equivalent of George Washington.

=== Articles === Rosen, DR; Siddique, T; Patterson, D; Figlewicz, DA; Sapp, P; Hentati, A; Donaldson, D; Goto, J; O'Regan, JP; Deng, HX; et al. (1993). "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis". Nature. 364 (6435): 362. Bibcode:1993Natur.364..362R. doi:10.1038/364362c0. PMID 8332197. Gusella, JF; Wexler, NS; Conneally, PM; Naylor, SL; Anderson, MA; Tanzi, RE; Watkins, PC; Ottina, K; Wallace, MR; Sakaguchi, AY; Young, AB; Shoulson, I; Bonilla, E; Martin, JB (1983). "A polymorphic DNA marker genetically linked to Huntington's Disease". Nature. 306 (5940): 234–238. Bibcode:1983Natur.306..234G. doi:10.1038/306234a0. PMID 6316146. S2CID 4320711. Tanzi, RE; Gusella, JF; Watkins, PC; Bruns, GAP; St; George-Hyslop, PH; Van Keuren, ML; Patterson, D; Pagan, S; Kurnit, DM; Neve, RL. (1987). "The amyloid beta protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus". Science. 235 (4791): 880–884. Bibcode:1987Sci...235..880T. doi:10.1126/science.2949367. PMID 2949367. Tanzi, RE; McClatchey, AI; Lamperti, ED; V-Komaroff, L; Gusella, JF; Neve, R (1988). "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease". Nature. 331 (6156): 528–530. Bibcode:1988Natur.331..528T. doi:10.1038/331528a0. PMID 2893290. S2CID 4277294.

Working at the newly relocated Institute for Social Research, Adorno collaborated on influential studies of authoritarianism, antisemitism, and propaganda that would later serve as models for sociological studies the institute carried out in post-war Germany. Upon his return to Frankfurt, Adorno was involved with the reconstitution of German intellectual life through debates with Karl Popper on the limitations of positivist science, critiques of Martin Heidegger's language of authenticity, writings on German responsibility for the Holocaust, and continued interventions into matters of public policy. As a writer of polemics in the tradition of Friedrich Nietzsche and Karl Kraus, Adorno delivered scathing critiques of contemporary Western culture. Adorno's posthumously published Aesthetic Theory (1970), which he had planned to dedicate to Samuel Beckett, is the culmination of a lifelong commitment to modern art, which seeks to revoke the "fatal separation" of feeling and understanding long demanded by the history of philosophy and explode the privilege aesthetics accords to content over form and contemplation over immersion. Adorno was nominated for the 1965 Nobel Prize in Literature by Helmut Viebrock.

=== Structure of isozymes === Mammalian GPx1, GPx2, GPx3, and GPx4 have been shown to be selenium-containing enzymes, whereas GPx6 is a selenoprotein in humans with cysteine-containing homologues in rodents. GPx1, GPx2, and GPx3 are homotetrameric proteins, whereas GPx4 has a monomeric structure. As the integrity of the cellular and subcellular membranes depends heavily on glutathione peroxidase, its antioxidative protective system itself depends heavily on the presence of selenium.

==== MeSH E05.196.309 – crystallography ==== MeSH E05.196.309.555 – neutron diffraction MeSH E05.196.309.711 – powder diffraction MeSH E05.196.309.742 – x-ray diffraction MeSH E05.196.309.742.225 – crystallography, x-ray

Sources: en.wikipedia.org

Frequently asked questions

What does the PT-141 code refer to?

The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.

Which receptor is considered the principal target?

MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.

How does it relate to melanotan II?

Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.

Which receptors does bremelanotide activate?

Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.

Network